Skip to content
  1. Home
  2. Anti-aging
  3. PTD-DBM

Anti-aging

PTD-DBM

Preclinical peptide that blocks a Wnt-pathway inhibitor (CXXC5) in hair follicles, designed to restore hair regrowth through molecular disinhibition.

Research chemical Anti-aging Recovery & healing

Reviewed 2026-09-12
Full name
Protein Transduction Domain–Dishevelled Binding Motif
Also known as
CXXC5 inhibitor, DBM peptide
Regulatory status
Research chemical | Preclinical stage (no human trials)

Origin

Developed after researchers found that DHT upregulates CXXC5 in balding-scalp dermal papilla cells, where CXXC5 normally suppresses the Wnt/beta-catenin signaling hair growth needs. PTD-DBM was designed to displace CXXC5 and restore that signaling, often paired experimentally with valproic acid.

Mechanism

The PTD domain enables cell penetration; the DBM domain competes with CXXC5 for Dishevelled (Dvl) binding, displacing CXXC5 and freeing up Wnt/beta-catenin signaling, which upregulates downstream hair-growth genes.

Research summary

Evidence

All evidence is preclinical. Mouse studies show stimulated hair regrowth and follicle neogenesis. As of 2026, no completed human clinical trials, Phase I safety data, or dosing studies exist.

Evidence tier: Research chemical — see the methodology note for how this is assessed.

Citations

No specific peer-reviewed citations indexed for this entry — see the research summary above for what evidence does exist.

Reported benefits

  • stimulation of hair follicle anagen phase (mouse models)
  • follicle neogenesis in rodents
  • reversal of DHT-mediated Wnt suppression (theoretical)

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
RouteReported protocol
Topical application (preclinical only)No human dosing protocols exist; unregulated vendors offer unvalidated topical formulations.

Side effects

  • unknown in humans; animal studies report no acute toxicity

Safety notes

Safety: No human safety data. Theoretical oncology concern: disinhibiting Wnt/beta-catenin, which is upregulated in several cancers, in genetically predisposed individuals. Contraindicated in pregnancy given the absence of reproductive toxicology data.
Community & reddit notes (anecdotal — not clinical evidence)

Used by underground hair-loss self-experimenters, often stacked with minoxidil, finasteride, and valproic acid. Anecdotal, uncontrolled reports of regrowth over 3-6 months.